- $1.82bn
- $1.70bn
- $89.08m
- 69
- 12
- 64
- 46
Annual income statement for RxSight, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.24 | 14.7 | 22.6 | 49 | 89.1 |
Cost of Revenue | |||||
Gross Profit | -1.82 | 1.71 | 4.52 | 21.3 | 53.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 48.3 | 50.1 | 75.4 | 112 | 141 |
Operating Profit | -46.1 | -35.4 | -52.8 | -63.3 | -51.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 126 | 27.6 | -48.7 | -66.7 | -48.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 126 | 27.6 | -48.7 | -66.8 | -48.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 126 | 27.6 | -48.7 | -66.8 | -48.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 26.1 | 3.37 | -48.7 | -66.8 | -48.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.974 | 0.128 | -1.78 | -2.36 | -1.38 |